<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01795599</url>
  </required_header>
  <id_info>
    <org_study_id>2012-005276-34</org_study_id>
    <secondary_id>2012-36</secondary_id>
    <nct_id>NCT01795599</nct_id>
  </id_info>
  <brief_title>Cervical Preparation for Surgical Abortion at 12-14 Weeks: a Prospective, Randomized, Evaluator-blinded, Multicenter, Controlled Comparison Between Mifepristone, Misoprostol and Their Combination</brief_title>
  <official_title>Cervical Preparation for Surgical Abortion at 12-14 Weeks: a Prospective, Randomized, Evaluator-blinded, Multicenter, Controlled Comparison Between Mifepristone, Misoprostol and Their Combination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      More than 100 000 surgical abortions are annually performed in France. About four in ten&#xD;
      women will have an abortion in their life. Abortion complications are cervical tearing&#xD;
      (0.1-1.18%), uterine perforation (0.09-19.8‰), hemorrhage (1.5‰) and infection (5-20%). These&#xD;
      complications can first compromise the vital prognosis and are involved in 10% of the&#xD;
      worldwide maternal mortality (20 000 women by year), then lead to infertility which is hard&#xD;
      to treat (uterine synechiae) or impossible to treat (hysterectomy for control of bleeding),&#xD;
      and are finally responsible for obstetrical pathologies as late miscarriages or premature&#xD;
      delivery due to cervical insufficiency. All that complications are linked to cervical&#xD;
      laceration of the surgical abortion, that can be reduced by the recommended use of&#xD;
      mifepristone or misoprostol as cervical preparation for the abortions after 12 weeks.&#xD;
      However, it does not exist data evaluating the superiority of one of the two molecules or&#xD;
      their combination. These data could optimize the cervical preparation and thus reduce the&#xD;
      abortion complications with a direct impact on maternal mortality, infertility and&#xD;
      obstetrical complications. Thus, it seems to be important to evaluate these two molecules and&#xD;
      their combination.&#xD;
&#xD;
      Objectives To compare mifepristone, misoprostol and their combination in the cervical&#xD;
      preparation of the surgical abortion between 12 and14 weeks for their efficacy, complications&#xD;
      and side-effects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>reduction of the bleeding</measure>
    <time_frame>24month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>reduction of the complications</measure>
    <time_frame>24 MONTHS</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">198</enrollment>
  <condition>Surgical Abortion</condition>
  <arm_group>
    <arm_group_label>mifepristone/misoprostol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>misoprostol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>mifepristone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mifegyne ®</intervention_name>
    <arm_group_label>mifepristone</arm_group_label>
    <arm_group_label>mifepristone/misoprostol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gymiso®</intervention_name>
    <arm_group_label>mifepristone/misoprostol</arm_group_label>
    <arm_group_label>misoprostol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Woman of 18 or more years old;&#xD;
&#xD;
          -  Woman presenting a only intra-uterine pregnancy, the term of which is upper to 11&#xD;
             LIMITED COMPANIES 6 days and inferior strictly to 14 LIMITED COMPANIES,&#xD;
             estimated(esteemed) by echography by a measure of the crânio-caudal length included&#xD;
             between 55 and 84 millimeters; ·Woman wishing a TERMINATION OF PREGNANCY;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  minor Woman;&#xD;
&#xD;
          -  Woman presenting a multiple pregnancy;&#xD;
&#xD;
          -  Woman presenting an uterine deformation (compartmentalized womb, cocked hat, fibroid&#xD;
             praevia);&#xD;
&#xD;
          -  Woman presenting a disorder of the coagulation defined by biological parameters&#xD;
             (TP(BUSINESS RATE,PRACTICAL CLASS,PRACTICAL CLASSES) &lt; 70 %, TCA report(relationship)&#xD;
             patient / witness &lt; 1,20);&#xD;
&#xD;
          -  Woman presenting an allergy or a sentimentality known about one of the active&#xD;
             substances or about one of the excipients;&#xD;
&#xD;
          -  Woman presenting a contraindication to the mifepristone: chronic suprarenal&#xD;
             insufficiency, unchecked severe asthma by treatment(processing), porphyrie hereditary,&#xD;
             allergy was known about the active substance or about one of the excipients;&#xD;
&#xD;
          -  Woman presenting a contraindication to the misoprostol: sentimentality in the active&#xD;
             substance, in one of the excipients or in the other prostaglandines;&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LOIC MONDOLONI</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique Hopitaux De Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>aubert AGOSTINI</last_name>
    <email>aubert.agostini@ap-hm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assistance Publique Hopitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>AUBERT AGOSTINI</last_name>
      <email>aubert.agostini@ap-hm.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <study_first_submitted>February 18, 2013</study_first_submitted>
  <study_first_submitted_qc>February 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2013</study_first_posted>
  <last_update_submitted>August 29, 2014</last_update_submitted>
  <last_update_submitted_qc>August 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mifepristone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

